title: The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis.
authors.affiliation: Bryn Mawr Skin and Cancer Institute, Rosemont, PA, U.S.A.
authors.forename: K
authors.initials: K
authors.lastname: Capriotti
authors.affiliation: Ophthalmology Consultants PC, Juan F. Luis Hospital, Christiansted, VI, U.S.A.
authors.forename: J A
authors.initials: JA
authors.lastname: Capriotti
authors.affiliation: Bryn Mawr Skin and Cancer Institute, Rosemont, PA, U.S.A.
authors.forename: S
authors.initials: S
authors.lastname: Lessin
authors.affiliation: Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, NY, U.S.A.|Division of Hematology and Oncology, Department of Medicine, Northport VA Medical Center, Northport, NY, U.S.A.
authors.forename: S
authors.initials: S
authors.lastname: Wu
authors.affiliation: Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, U.S.A.
authors.forename: S
authors.initials: S
authors.lastname: Goldfarb
authors.affiliation: Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, U.S.A.
authors.forename: V R
authors.initials: VR
authors.lastname: Belum
authors.affiliation: Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, U.S.A.
authors.forename: M E
authors.initials: ME
authors.lastname: Lacouture
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D006801:Humans; D009260:Nail Diseases / Q000139:chemically induced*; D009369:Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000009:adverse effects*; D050257:Tubulin Modulators / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D050257:Tubulin Modulators; D000077143:Docetaxel; D017239:Paclitaxel